Can Moderna's Aggressive Cost Cuts Help Turn Things Around for Its Stock?
Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.
Moderna norovirus vaccine trial on hold by US FDA over neurological side effect
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Moderna Shares Fall After Reports of HHS Review of Bird Flu Vaccine Contract
Moderna shares fell 3% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine. Moderna was awarded the ...
Moderna beats on revenue but loses more than expected as it scales down manufacturing
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Outlook Disappoints
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...
Moderna to Present at Upcoming Conferences in March 2025
Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...
Moderna Stock Falls on Earnings Report. The Results Reaffirm a Grim Picture for Vaccine Maker.
The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...
These Stocks Moved the Most Today: Nvidia, Super Micro, Snowflake, Moderna, Tesla, Salesforce, Vistra, and More
Nvidia reports better-than-expected fourth-quarter earnings as revenue jumps 78% on demand for the company’s ...